Table 3.

Univariate comparisons for patients with multiple myeloma: overall survival and progression-free survival rates

Prognostic factors at time of transplantationOverall survivalProgression-free survival
Relative risk95% CIPRelative risk95% CIP
Abnormal       
cytogenetics vs normal .39 .23-.68 .001 .44 .27-.70 < .0007 
Age > 50 y vs < 50 y 1.03 .6-1.8 .91 1.04 .65-1.67 .86  
ALC ≥ 500 cells/μL vs < 500 cells/μL .24 .14-.42 < .0001 .34 .21-.55 < .0001 
ANC ≥ 500 cells/μL vs < 500 cells/μL .40 .12-1.33 .14 .37 .13-1.04 .06 
β2M > 2.7 mg/L vs ≤ 2.7 mg/L .58 .33-1.01 .054 .7 .44-1.11 .13  
Bone marrow       
plasma cells ≥ 40% vs < 40% .49 .3-.8 .007 .55 .35-.87 .01 
Circulating plasma cells .39 .23-.68 .0007 .46 .28-.77 .003  
CRP > 0.8 mg/dL vs ≤ 0.8 mg/dL .57 .31-1.04 .067 .65 .38-1.1 .11  
LDH level normal for age/sex vs > normal .45 .21-.95 .037 .45 .24-.86 .015  
PCLI ≥ 1% vs < 1% .34 .2-.6 .0001 .34 .21-.55 < .0001 
Platelet level > 20 × 109/L vs ≤ 20 × 109/L .18 .09-.36 < .0001 .3 .16-.57 .00024 
No. pretransplant chemotherapy regimens 1.58 1.05-2.38 .028 1.7 1.18-2.44 .004 
Primary refractory       
disease vs plateau/response NA3-150   2.94 .63-13.7 .17 
Relapse off       
therapy vs plateau/response 1.163-151 .5-2.7 .73 5.99 1.43-25.1 .014 
Relapse on       
therapy vs plateau/response 3.083-151 1.4-6.76 .005 13.94 3.3-58.5 .0003 
Stem cell source       
PBSCs vs BM .45 .26-.78 .004 .48 .29-.79 .004 
Prognostic factors at time of transplantationOverall survivalProgression-free survival
Relative risk95% CIPRelative risk95% CIP
Abnormal       
cytogenetics vs normal .39 .23-.68 .001 .44 .27-.70 < .0007 
Age > 50 y vs < 50 y 1.03 .6-1.8 .91 1.04 .65-1.67 .86  
ALC ≥ 500 cells/μL vs < 500 cells/μL .24 .14-.42 < .0001 .34 .21-.55 < .0001 
ANC ≥ 500 cells/μL vs < 500 cells/μL .40 .12-1.33 .14 .37 .13-1.04 .06 
β2M > 2.7 mg/L vs ≤ 2.7 mg/L .58 .33-1.01 .054 .7 .44-1.11 .13  
Bone marrow       
plasma cells ≥ 40% vs < 40% .49 .3-.8 .007 .55 .35-.87 .01 
Circulating plasma cells .39 .23-.68 .0007 .46 .28-.77 .003  
CRP > 0.8 mg/dL vs ≤ 0.8 mg/dL .57 .31-1.04 .067 .65 .38-1.1 .11  
LDH level normal for age/sex vs > normal .45 .21-.95 .037 .45 .24-.86 .015  
PCLI ≥ 1% vs < 1% .34 .2-.6 .0001 .34 .21-.55 < .0001 
Platelet level > 20 × 109/L vs ≤ 20 × 109/L .18 .09-.36 < .0001 .3 .16-.57 .00024 
No. pretransplant chemotherapy regimens 1.58 1.05-2.38 .028 1.7 1.18-2.44 .004 
Primary refractory       
disease vs plateau/response NA3-150   2.94 .63-13.7 .17 
Relapse off       
therapy vs plateau/response 1.163-151 .5-2.7 .73 5.99 1.43-25.1 .014 
Relapse on       
therapy vs plateau/response 3.083-151 1.4-6.76 .005 13.94 3.3-58.5 .0003 
Stem cell source       
PBSCs vs BM .45 .26-.78 .004 .48 .29-.79 .004 

CI indicates confidence interval; β2M, β2-microglobulin; CRP, C-reactive protein; PCLI, plasma cell–labeling index; for other abbreviations, see Table 1.

F3-150

Level absorbed into model since plateau/response level omitted.

F3-151

Primary refractory level.

or Create an Account

Close Modal
Close Modal